Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benjamin Leder, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21AR069871 (LEDER, BENJAMIN Z) May 1, 2016 - Apr 30, 2019
    NIH/NIAMS
    Consolidating Skeletal Benefits after Short-Term Combination Osteoporosis Therapy; The DATA-EX Study
    Role: Principal Investigator
  2. K24AR067847 (LEDER, BENJAMIN Z) May 1, 2015 - Apr 30, 2020
    NIH/NIAMS
    Novel combination therapies in the treatment of osteoporosis
    Role: Principal Investigator
  3. R01AG025099 (LEDER, BENJAMIN Z) Sep 1, 2005 - Jul 31, 2011
    NIH/NIA
    Aromatase inhibition in elderly hypogonadal men
    Role: Principal Investigator
  4. K23RR016310 (LEDER, BENJAMIN Z) Sep 1, 2001 - Aug 31, 2006
    NIH/NCRR
    DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE
    Role: Principal Investigator
  5. F32AR008574 (LEDER, BENJAMIN Z) Sep 1, 1999
    NIH/NIAMS
    DIFFERENTIAL EFFECTS OF ANDROGENS AND ESTROGENS ON BONE
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Leder BZ. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy. JBMR Plus. 2018 Mar; 2(2):62-68. PMID: 30283892.
    View in: PubMed
  2. Leder BZ. An Essential Warning. J Bone Miner Res. 2018 Feb; 33(2):188-189. PMID: 29232486.
    View in: PubMed
  3. Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2018 02; 29(2):323-328. PMID: 29167971.
    View in: PubMed
  4. Tsai JN, Nishiyama KK, Lin D, Yuan A, Lee H, Bouxsein ML, Leder BZ. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study. J Bone Miner Res. 2017 Oct; 32(10):2001-2009. PMID: 28608571.
    View in: PubMed
  5. Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ. Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial. J Clin Densitom. 2017 Oct - Dec; 20(4):507-512. PMID: 28624340.
    View in: PubMed
  6. Leder BZ. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. Curr Osteoporos Rep. 2017 04; 15(2):110-119. PMID: 28303448.
    View in: PubMed
  7. Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone. 2017 May; 98:54-58. PMID: 28286299.
    View in: PubMed
  8. Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone. 2017 02; 95:20-25. PMID: 27840301.
    View in: PubMed
  9. Leder BZ, Tsai JN, Burnett-Bowie SA, Bouxsein ML, Neer RM. Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. Bone. 2016 08; 89:73-74. PMID: 27157641.
    View in: PubMed
  10. Tsai JN, Uihlein AV, Burnett-Bowie SM, Neer RM, Derrico NP, Lee H, Bouxsein ML, Leder BZ. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016 05; 101(5):2023-30. PMID: 26964731.
    View in: PubMed
  11. Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016 Mar 01; 126(3):1114-25. PMID: 26901812; PMCID: PMC4767351.
  12. Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. J Clin Densitom. 2016 Jul-Sep; 19(3):346-51. PMID: 26900146.
    View in: PubMed
  13. Mitchell DM, Leder BZ, Cagliero E, Mendoza N, Henao MP, Hayden DL, Finkelstein JS, Burnett-Bowie SA. Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Am J Clin Nutr. 2015 Aug; 102(2):385-92. PMID: 26156733; PMCID: PMC4515870.
  14. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19; 386(9999):1147-55. PMID: 26144908; PMCID: PMC4620731.
  15. Tsai JN, Zhu Y, Foley K, Lee H, Burnett-Bowie SA, Neer RM, Leder BZ. Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. J Clin Endocrinol Metab. 2015 Jul; 100(7):2718-23. PMID: 25933031.
    View in: PubMed
  16. Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015 Jan; 30(1):39-45. PMID: 25043459.
    View in: PubMed
  17. Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015 Feb; 100(2):697-706. PMID: 25393645.
    View in: PubMed
  18. Diem SJ, Joffe H, Larson JC, Tsai JN, Guthrie KA, LaCroix AZ, Ensrud KE, Freeman EW, Leder BZ. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab. 2014 Sep; 99(9):E1732-7. PMID: 25014001; PMCID: PMC4154080.
  19. Yu EW, Kumbhani R, Siwila-Sackman E, DeLelys M, Preffer FI, Leder BZ, Wu JY. Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women. J Bone Miner Res. 2014 Jun; 29(6):1380-6. PMID: 24420643; PMCID: PMC4564394.
  20. Uihlein AV, Finkelstein JS, Lee H, Leder BZ. FSH suppression does not affect bone turnover in eugonadal men. J Clin Endocrinol Metab. 2014 Jul; 99(7):2510-5. PMID: 24646101; PMCID: PMC4079307.
  21. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014 May; 99(5):1694-700. PMID: 24517156.
    View in: PubMed
  22. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 Sep 12; 369(11):1011-22. PMID: 24024838; PMCID: PMC4142768.
  23. Bollerslev J, Harris ST, Leder BZ. Hypoparathyroidism. J Clin Endocrinol Metab. 2013 Jun; 98(6):39A-40A. PMID: 23729019.
    View in: PubMed
  24. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013 Jul 06; 382(9886):50-6. PMID: 23683600; PMCID: PMC4083737.
  25. Bollerslev J, Harris ST, Leder BZ. Medicines and bone loss. J Clin Endocrinol Metab. 2013 Apr; 98(4):33A-4A. PMID: 23564951.
    View in: PubMed
  26. Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Sep; 15(3):308-12. PMID: 22641239; PMCID: PMC3671885.
  27. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am. 2012 Sep; 41(3):507-25. PMID: 22877427.
    View in: PubMed
  28. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Sep 10; 30(26):3271-6. PMID: 22649143; PMCID: PMC3434987.
  29. Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol. 2012 Apr; 7(4):624-31. PMID: 22300739.
    View in: PubMed
  30. Bollerslev J, Harris ST, Leder BZ. Glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 2012 Feb; 97(2):35A. PMID: 22312098.
    View in: PubMed
  31. Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl C. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec; 26(12):2827-33. PMID: 21898590; PMCID: PMC3222788.
  32. Bollerslev J, Harris ST, Leder BZ. Bisphosphonates for osteoporosis: benefits and risks. J Clin Endocrinol Metab. 2011 Sep; 96(9):27A, 28A. PMID: 21896893.
    View in: PubMed
  33. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab. 2011 Nov; 96(11):E1848-51. PMID: 21865370; PMCID: PMC3205893.
  34. Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009 Dec; 182(6):2670-5. PMID: 19836774; PMCID: PMC2900763.
  35. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009 Dec; 94(12):4785-92. PMID: 19820017; PMCID: PMC2795655.
  36. Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009 Oct; 24(10):1681-5. PMID: 19419295; PMCID: PMC2743281.
  37. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20; 361(8):745-55. PMID: 19671656; PMCID: PMC3038121.
  38. Leder B, Silverberg SJ, Stewart AF. Patient information page from the Hormone Foundation. High blood calcium (Hypercalcemia). J Clin Endocrinol Metab. 2009 Jul; 94(7):2670. PMID: 19593858.
    View in: PubMed
  39. Saad F, Smith MR, Egerdie B, Tammela TL, Feldman RA, Heracek J, Szwedowski M, Ke C, Leder B, Goessl C. Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). J Clin Oncol. 2009 May 20; 27(15_suppl):5056. PMID: 27962972.
    View in: PubMed
  40. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009 Aug; 94(8):2915-21. PMID: 19435827; PMCID: PMC2730878.
  41. Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Jüppner H, Neer RM. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009 Jul; 94(7):2495-501. PMID: 19401368; PMCID: PMC2708954.
  42. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2009 Jan; 70(1):116-23. PMID: 18616708.
    View in: PubMed
  43. Travison TG, Araujo AB, Beck TJ, Williams RE, Clark RV, Leder BZ, McKinlay JB. Relation between serum testosterone, serum estradiol, sex hormone-binding globulin, and geometrical measures of adult male proximal femur strength. J Clin Endocrinol Metab. 2009 Mar; 94(3):853-60. PMID: 19106273; PMCID: PMC2681275.
  44. Araujo AB, Travison TG, Leder BZ, McKinlay JB. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab. 2008 Jun; 93(6):2135-41. PMID: 18364385; PMCID: PMC2435644.
  45. Leder BZ. Is parathyroid hormone (1-84) a safe and effective treatment for postmenopausal osteoporosis? Nat Clin Pract Endocrinol Metab. 2007 Nov; 3(11):746-7. PMID: 17768406.
    View in: PubMed
  46. Leder BZ, Araujo AB, Travison TG, McKinlay JB. Racial and ethnic differences in bone turnover markers in men. J Clin Endocrinol Metab. 2007 Sep; 92(9):3453-7. PMID: 17579203.
    View in: PubMed
  47. Leder B. Gonadal steroids and bone metabolism in men. Curr Opin Endocrinol Diabetes Obes. 2007 Jun; 14(3):241-6. PMID: 17940446.
    View in: PubMed
  48. Leder BZ. Testosterone, estradiol and aromatase inhibitor therapy in elderly men. J Steroid Biochem Mol Biol. 2007 Aug-Sep; 106(1-5):162-7. PMID: 17600698.
    View in: PubMed
  49. Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007 Apr; 40(4):913-8. PMID: 17157573; PMCID: PMC2083121.
  50. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug; 91(8):2882-7. PMID: 16684825.
    View in: PubMed
  51. Lee H, Finkelstein JS, Miller M, Comeaux SJ, Cohen RI, Leder BZ. Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2006 Mar; 91(3):1069-75. PMID: 16352679.
    View in: PubMed
  52. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005 Dec; 16(12):1487-94. PMID: 15856361.
    View in: PubMed
  53. Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf). 2005 Feb; 62(2):228-35. PMID: 15670201.
    View in: PubMed
  54. Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004 Mar; 89(3):1174-80. PMID: 15001605.
    View in: PubMed
  55. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003 Jan; 88(1):204-10. PMID: 12519853.
    View in: PubMed
  56. Leder BZ, Leblanc KM, Longcope C, Lee H, Catlin DH, Finkelstein JS. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab. 2002 Dec; 87(12):5449-54. PMID: 12466335.
    View in: PubMed
  57. Catlin DH, Leder BZ, Ahrens BD, Hatton CK, Finkelstein JS. Effects of androstenedione administration on epitestosterone metabolism in men. Steroids. 2002 Jun; 67(7):559-64. PMID: 11996927.
    View in: PubMed
  58. Leder BZ, Catlin DH, Longcope C, Ahrens B, Schoenfeld DA, Finkelstein JS. Metabolism of orally administered androstenedione in young men. J Clin Endocrinol Metab. 2001 Aug; 86(8):3654-8. PMID: 11502792.
    View in: PubMed
  59. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2001 Feb; 86(2):511-6. PMID: 11158001.
    View in: PubMed
  60. Catlin DH, Leder BZ, Ahrens B, Starcevic B, Hatton CK, Green GA, Finkelstein JS. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. JAMA. 2000 Nov 22-29; 284(20):2618-21. PMID: 11086369.
    View in: PubMed
  61. Leder BZ, Kronenberg HM. Gastroenterologists and choosing the right bisphosphonate. Gastroenterology. 2000 Sep; 119(3):866-9. PMID: 10982780.
    View in: PubMed
  62. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA. 2000 Feb 09; 283(6):779-82. PMID: 10683057.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Leder's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (211)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.